COLL Q2 2023 Earnings — Collegium Pharmaceutical, Inc. Revenue & Financial Results | Market Cap Arena

COLLCollegium Pharmaceutical, Inc.

$1B

Q2 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$136M+9.7% YoY

Gross Profit

$74M54.5% margin

Operating Income

$36M26.3% margin

Net Income

$13M9.6% margin

EPS (Diluted)

$0.34

QoQ Revenue Growth

-6.4%

Cash Flow

Operating Cash Flow

$100M

Free Cash Flow

$100M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$1.0B

Stockholders' Equity

$201M

Cash & Equivalents

$284M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$136M	$124M	+9.7%
Gross Profit	$74M	$52M	+41.0%
Operating Income	$36M	$11M	+220.7%
Net Income	$13M	-$5M	+350.6%

Revenue Segments

Belbuca

$43M32%

Xtampza ER

$41M30%

Nucynta IR

$28M21%

Nucynta ER

$19M14%

Symproic

$4M3%